- Home
- KLIC vs TNGX Comparison
KLIC vs TNGX Comparison
Compare KLIC & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KLIC | TNGX |
|---|---|---|
| Founded | 1951 | 2014 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.9B |
| IPO Year | 2004 | 2020 |
Fundamental Metrics
Financial Performance| Metric | KLIC | TNGX |
|---|---|---|
| Price | $107.93 | $21.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | ★ $54.67 | $21.78 |
| AVG Volume (30 Days) | 930.2K | ★ 2.6M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.98% | N/A |
| EPS Growth | ★ 100.32 | 26.89 |
| EPS | ★ 0.98 | N/A |
| Revenue | ★ $654,081,000.00 | $62,384,000.00 |
| Revenue This Year | $45.81 | N/A |
| Revenue Next Year | $11.35 | N/A |
| P/E Ratio | $110.57 | ★ N/A |
| Revenue Growth | N/A | ★ 48.29 |
| 52 Week Low | $31.33 | $3.12 |
| 52 Week High | $110.78 | $28.41 |
Technical Indicators
Market Signals| Indicator | KLIC | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 64.96 | 48.28 |
| Support Level | $94.31 | $20.05 |
| Resistance Level | N/A | $22.01 |
| Average True Range (ATR) | 5.29 | 1.71 |
| MACD | -0.41 | -0.01 |
| Stochastic Oscillator | 82.09 | 33.84 |
Price Performance
Historical ComparisonAbout KLIC Kulicke and Soffa Industries Inc.
Kulicke & Soffa Industries Inc. is a United States-based company that is principally engaged in designing, manufacturing, and selling capital equipment and expendable tools that are used for assembling semiconductor devices. The company has four reportable segments, which include Ball Bonding Equipment, Wedge Bonding Equipment, Advanced Solutions, and Aftermarket Products and Services. Its Ball Bonding Equipment segment which generates the majority of the revenue for the company includes results of the company from the design, development, manufacture and sale of ball bonding equipment and wafer level bonding equipment. The majority of its customers are located in the Asia-pacific region.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.